KR20240048010A - 인터루킨-1 수용체 관련 키나제의 이작용성 분해제 및 이의 치료 용도 - Google Patents

인터루킨-1 수용체 관련 키나제의 이작용성 분해제 및 이의 치료 용도 Download PDF

Info

Publication number
KR20240048010A
KR20240048010A KR1020247008466A KR20247008466A KR20240048010A KR 20240048010 A KR20240048010 A KR 20240048010A KR 1020247008466 A KR1020247008466 A KR 1020247008466A KR 20247008466 A KR20247008466 A KR 20247008466A KR 20240048010 A KR20240048010 A KR 20240048010A
Authority
KR
South Korea
Prior art keywords
mmol
optionally substituted
alkyl
pyridin
thiadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247008466A
Other languages
English (en)
Korean (ko)
Inventor
와일리 팔머
제프리 우
존 리
케렘 오즈보야
팀 케인
Original Assignee
누릭스 테라퓨틱스 인코포레이티드
길리애드 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 누릭스 테라퓨틱스 인코포레이티드, 길리애드 사이언시즈, 인코포레이티드 filed Critical 누릭스 테라퓨틱스 인코포레이티드
Publication of KR20240048010A publication Critical patent/KR20240048010A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247008466A 2021-08-18 2022-08-18 인터루킨-1 수용체 관련 키나제의 이작용성 분해제 및 이의 치료 용도 Pending KR20240048010A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163234606P 2021-08-18 2021-08-18
US63/234,606 2021-08-18
PCT/US2022/040765 WO2023023255A1 (en) 2021-08-18 2022-08-18 Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof

Publications (1)

Publication Number Publication Date
KR20240048010A true KR20240048010A (ko) 2024-04-12

Family

ID=83594510

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247008466A Pending KR20240048010A (ko) 2021-08-18 2022-08-18 인터루킨-1 수용체 관련 키나제의 이작용성 분해제 및 이의 치료 용도

Country Status (26)

Country Link
US (2) US11976071B2 (https=)
EP (2) EP4512402A3 (https=)
JP (2) JP7774709B2 (https=)
KR (1) KR20240048010A (https=)
CN (1) CN117813307A (https=)
AR (1) AR126826A1 (https=)
AU (2) AU2022330009B2 (https=)
CA (1) CA3226118A1 (https=)
CL (1) CL2024000446A1 (https=)
CO (1) CO2024001524A2 (https=)
CR (1) CR20240080A (https=)
DK (1) DK4367118T3 (https=)
DO (1) DOP2024000028A (https=)
ES (1) ES3024057T3 (https=)
FI (1) FI4367118T3 (https=)
HR (1) HRP20250402T1 (https=)
HU (1) HUE070709T2 (https=)
IL (1) IL310446A (https=)
LT (1) LT4367118T (https=)
MX (1) MX2024002153A (https=)
PE (1) PE20241618A1 (https=)
PL (1) PL4367118T3 (https=)
PT (1) PT4367118T (https=)
SI (1) SI4367118T1 (https=)
TW (2) TW202535879A (https=)
WO (1) WO2023023255A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4107158A1 (en) 2020-02-19 2022-12-28 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
US20240208923A1 (en) 2021-03-10 2024-06-27 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc6a19 function
FI4367118T3 (fi) 2021-08-18 2025-04-09 Nurix Therapeutics Inc Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö
WO2023186069A1 (zh) * 2022-03-31 2023-10-05 石药集团中奇制药技术（石家庄）有限公司 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途
KR20260022390A (ko) 2023-06-08 2026-02-19 누릭스 테라퓨틱스 인코포레이티드 Smarca2의 선택적 분해제로서의 이작용성 아진 접합체 및 이의 치료적 용도
WO2025149070A1 (zh) * 2024-01-10 2025-07-17 甘李药业股份有限公司 一种新型靶向白细胞介素1受体关联激酶4(irak4)的蛋白降解嵌合体化合物的合成及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7041298B2 (en) 2000-09-08 2006-05-09 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7030112B2 (en) 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
US9464326B2 (en) 2012-03-22 2016-10-11 University Of Maryland, Baltimore Total and phosphorylated IL-1 receptor-associated kinase-1 and IL-1 receptor-associated kinase-4 as a biomarker for cancer progression and chemotherapy resistance
TW201609693A (zh) 2014-01-03 2016-03-16 必治妥美雅史谷比公司 雜芳基取代之菸鹼醯胺化合物
AU2015247817C1 (en) 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
TW201718571A (zh) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo
US10487329B2 (en) 2015-10-29 2019-11-26 Children's Hospital Medical Center Methods and compositions for the treatment of head and neck cancer
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2018071606A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3532164A4 (en) 2016-10-28 2020-10-07 Children's Hospital Medical Center TREATMENT OF IRAQ ASSOCIATED DISEASES ACTIVATED
BR112019015484A2 (pt) 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
WO2018232288A1 (en) 2017-06-16 2018-12-20 Genentech, Inc. Diagnostic and therapeutic methods for irak4-mediated disorders and conditions
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019103196A1 (ko) 2017-11-24 2019-05-31 엘지전자 주식회사 무선 통신 시스템에서 빔을 리포팅하는 방법 및 장치
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019160915A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
WO2020036830A1 (en) 2018-08-13 2020-02-20 Gilead Sciences, Inc. Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
TWI727392B (zh) 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4038066A1 (en) 2019-10-01 2022-08-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
US11820781B2 (en) * 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
EP4107158A1 (en) * 2020-02-19 2022-12-28 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
WO2021180103A1 (en) 2020-03-11 2021-09-16 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
MX2022016061A (es) 2020-06-17 2023-02-02 Kymera Therapeutics Inc Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos.
WO2021255212A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Braf degraders
US20240208923A1 (en) 2021-03-10 2024-06-27 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc6a19 function
CA3217892A1 (en) 2021-05-03 2022-11-10 Joel Mcintosh Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
US12018016B2 (en) 2021-08-18 2024-06-25 Amgen Inc. Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors
FI4367118T3 (fi) 2021-08-18 2025-04-09 Nurix Therapeutics Inc Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö
TW202321229A (zh) 2021-08-18 2023-06-01 美商富曼西公司 殺真菌的取代的雜環化合物

Also Published As

Publication number Publication date
HUE070709T2 (hu) 2025-06-28
TWI886406B (zh) 2025-06-11
FI4367118T3 (fi) 2025-04-09
JP7820584B2 (ja) 2026-02-25
AR126826A1 (es) 2023-11-15
DOP2024000028A (es) 2024-04-15
HRP20250402T1 (hr) 2025-05-09
MX2024002153A (es) 2024-03-08
CN117813307A (zh) 2024-04-02
LT4367118T (lt) 2025-04-10
CL2024000446A1 (es) 2024-07-26
US12570662B2 (en) 2026-03-10
CO2024001524A2 (es) 2024-02-26
EP4512402A3 (en) 2025-04-30
AU2025234314A1 (en) 2025-10-16
JP2024531273A (ja) 2024-08-29
PE20241618A1 (es) 2024-08-07
IL310446A (en) 2024-03-01
US11976071B2 (en) 2024-05-07
PL4367118T3 (pl) 2025-05-26
PT4367118T (pt) 2025-04-16
EP4367118A1 (en) 2024-05-15
TW202315632A (zh) 2023-04-16
CR20240080A (es) 2024-04-09
CA3226118A1 (en) 2023-02-23
AU2022330009A1 (en) 2024-01-25
WO2023023255A1 (en) 2023-02-23
DK4367118T3 (da) 2025-03-24
EP4512402A2 (en) 2025-02-26
AU2022330009B2 (en) 2025-09-25
US20230120619A1 (en) 2023-04-20
US20240417402A1 (en) 2024-12-19
SI4367118T1 (sl) 2025-06-30
EP4367118B1 (en) 2025-01-29
JP7774709B2 (ja) 2025-11-21
TW202535879A (zh) 2025-09-16
JP2025068015A (ja) 2025-04-24
ES3024057T3 (en) 2025-06-03

Similar Documents

Publication Publication Date Title
JP7820584B2 (ja) インターロイキン－１受容体関連キナーゼの二官能性分解剤及びその治療的使用
KR20200100709A (ko) 4-아자인돌 화합물
KR20230008176A (ko) 조혈 전구세포 키나아제의 이작용성 분해제 및 이의 치료적 용도
KR20220016049A (ko) Btk 억제제 고리 유도체, 이의 제조 방법 및 이의 약제학적 응용
TW201938555A (zh) Kras g12c抑制劑
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
EP2858994A1 (en) Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
CA2962578A1 (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
KR20240101654A (ko) 조혈 전구세포 키나아제의 이작용성 분해제 및 이의 치료적 용도
KR20260022390A (ko) Smarca2의 선택적 분해제로서의 이작용성 아진 접합체 및 이의 치료적 용도
HK40121612A (en) Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
HK40108095A (en) Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
HK40108095B (en) Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
EA051302B1 (ru) Бифункциональные биодеструкторы киназы, ассоциинированной с рецептором интерлейкина-1, и их терапевтическое применение
KR20240016977A (ko) 2,8-디아자스피로[4.5]데칸 화합물
HK40107816A (zh) 白介素-1受体相关激酶的双官能降解物及其治疗用途
KR20250133441A (ko) 2,4-디아닐리노피리미딘 기반의 오로라-a 키나아제 선택적 분해 유도 화합물
TW202225163A (zh) 芳香雜環類化合物、藥物組合物及其應用
HK40115438A (zh) 造血祖细胞激酶的双功能降解剂及其治疗用途
TW202500141A (zh) 作為ｒｉｐｋ１抑制劑的異㗁唑啶及其用途（二）
CN115557946A (zh) 杂环内酰胺类化合物，包含其的药物组合物及其用途

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701